These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. Fatal hymenoptera venom anaphylaxis by undetected clonal mast cell disorder: A better identification of high risk patients is needed. Chatain C; Sedillot N; Thomas M; Pernollet M; Bocquet A; Boccon-Gibod I; Bouillet L; Leccia MT Rev Med Interne; 2021 Dec; 42(12):869-874. PubMed ID: 34776279 [TBL] [Abstract][Full Text] [Related]
28. Clonal mast cell disorders and hereditary α-tryptasemia as risk factors for anaphylaxis. Kačar M; Rijavec M; Šelb J; Korošec P Clin Exp Allergy; 2023 Apr; 53(4):392-404. PubMed ID: 36654513 [TBL] [Abstract][Full Text] [Related]
29. [Tryptase: A practical guide for the physician]. Lobbes H; Reynaud Q; Mainbourg S; Lega JC; Durieu I; Durupt S Rev Med Interne; 2020 Nov; 41(11):748-755. PubMed ID: 32712042 [TBL] [Abstract][Full Text] [Related]
30. Mimics of Allergy and Angioedema: Scombroid, Mast Cell Activation Disorders, and Hereditary Alpha Tryptasemia. Thomas EG; Thomas DJ Immunol Allergy Clin North Am; 2023 Aug; 43(3):553-568. PubMed ID: 37394259 [TBL] [Abstract][Full Text] [Related]
31. Incorporating Tryptase Genotyping Into the Workup and Diagnosis of Mast Cell Diseases and Reactions. Lyons JJ; Greiner G; Hoermann G; Metcalfe DD J Allergy Clin Immunol Pract; 2022 Aug; 10(8):1964-1973. PubMed ID: 35597543 [TBL] [Abstract][Full Text] [Related]
32. Venom immunotherapy in patients with mastocytosis and hymenoptera venom anaphylaxis. González-de-Olano D; Alvarez-Twose I; Vega A; Orfao A; Escribano L Immunotherapy; 2011 May; 3(5):637-51. PubMed ID: 21554093 [TBL] [Abstract][Full Text] [Related]
34. Mechanisms of activation of human mast cells and basophils by general anesthetic drugs. Marone G; Stellato C; Mastronardi P; Mazzarella B Ann Fr Anesth Reanim; 1993; 12(2):116-25. PubMed ID: 7690200 [TBL] [Abstract][Full Text] [Related]
35. Reversible Elevation of Tryptase Over the Individual's Baseline: Why is It the Best Biomarker for Severe Systemic Mast Cell Activation and MCAS? Valent P; Akin C; Arock M Curr Allergy Asthma Rep; 2024 Mar; 24(3):133-141. PubMed ID: 38308674 [TBL] [Abstract][Full Text] [Related]
36. Pseudoanaphylaxis. Russell WJ; Smith WB Anaesth Intensive Care; 2006 Dec; 34(6):801-3. PubMed ID: 17183902 [TBL] [Abstract][Full Text] [Related]
37. Mechanisms Governing Anaphylaxis: Inflammatory Cells, Mediators, Endothelial Gap Junctions and Beyond. Nguyen SMT; Rupprecht CP; Haque A; Pattanaik D; Yusin J; Krishnaswamy G Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360549 [TBL] [Abstract][Full Text] [Related]
38. Pediatric Expression of Mast Cell Activation Disorders. Broesby-Olsen S; Carter M; Kjaer HF; Mortz CG; Møller MB; Kristensen TK; Bindslev-Jensen C; Agertoft L Immunol Allergy Clin North Am; 2018 Aug; 38(3):365-377. PubMed ID: 30007457 [TBL] [Abstract][Full Text] [Related]
39. Clonal mast cell disorders in patients with severe Hymenoptera venom allergy and normal serum tryptase levels. Zanotti R; Lombardo C; Passalacqua G; Caimmi C; Bonifacio M; De Matteis G; Perbellini O; Rossini M; Schena D; Busa M; Marcotulli MC; Bilò MB; Franchini M; Marchi G; Simioni L; Bonadonna P J Allergy Clin Immunol; 2015 Jul; 136(1):135-9. PubMed ID: 25605272 [TBL] [Abstract][Full Text] [Related]
40. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview. Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME; J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]